Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Cleveland, Ohio

This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
11338
Shown on this page
12
Current sort
Recently updated
Location scope
Cleveland, OH
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Cleveland, Ohio. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 553–564 of 11,338 matching trials in Cleveland, OH.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Cleveland

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Not applicable Interventional

Implant for Walking After Incomplete SCI

NCT06965127
View directory record Official record
Conditions
Spinal Cord Injury (SCI), Gait
Interventions
NNP-LE
Device
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Recruiting No phase listed Observational

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Multiple Sclerosis
Interventions
No Intervention
Other
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
111
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Not yet recruiting Not applicable Interventional

Culinary And Lifestyle Medicine Education for Cancer Risk Reduction in Survivors of Breast Cancer

NCT07906990
View directory record Official record
Conditions
Breast Cancer
Interventions
Living Cancer CALM education intervention
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Recruiting Phase 2Phase 3 Interventional

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions
Adagrasib, Pembrolizumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
220
States / cities
Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Recruiting Phase 1 Interventional

SW-682 in Advanced Solid Tumors

NCT06251310
View directory record Official record
Conditions
Advanced Solid Tumor, Mesothelioma, Malignant
Interventions
SW-682, Combination Therapy
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Recruiting Phase 3 Interventional

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia
Interventions
mocravimod
Drug
Lead sponsor
Priothera SAS
Industry
Eligibility
18 Years to 75 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Active, not recruiting Phase 2 Interventional Results available

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

NCT03994796
View directory record Official record
Conditions
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
435
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Active, not recruiting Phase 3 Interventional

A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

NCT07363720
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
Interventions
TAK-861, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
11
States / cities
Redwood City, California • Brandon, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Recruiting Phase 2Phase 3 Interventional

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Interventions
Zanzalintinib, Everolimus
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

NCT04675151
View directory record Official record
Conditions
Presbyopia
Interventions
Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Placebo
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
40 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
17
States / cities
Laguna Hills, California • Newport Beach, California • Crystal River, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

NCT03960866
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST
Recruiting Not applicable Interventional

Clareon TruPlus Study

NCT07502456
View directory record Official record
Conditions
Aphakia, Astigmatism
Interventions
Clareon TruPlus Monofocal Non-Toric IOL, Clareon TruPlus Monofocal Toric IOL, Phacoemulsification
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
22 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Phoenix, Arizona • Brecksville, Ohio • Mt. Pleasant, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 7:37 AM EST